An electron microscopic study of MPTP-induced inclusion bodies in an old monkey.

No abstract is available for this paper.

• Publication year

  1988

• Venue

  Brain Research

• Publication date

  1988-05-10

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/0006-8993(88)91111-0PMID 3260534
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pick body-like inclusions in the dentate fascia of the hippocampus in Alzheimer's disease

  2004cited by this paper
• Light- and electron-microscopic studies of intracytoplasmic acidophilic granules in the human locus ceruleus and substantia nigra

  2004cited by this paper
• Overview of morphological changes in Parkinson's disease.

  1987cited by this paper
• Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a neurochemical and morphological reassessment.

  1986cited by this paper
• Locus ceruleus lesions and eosinophilic inclusions in MPTP‐treated monkeys

  1986cited by this paper
• Age factors loom in parkinsonian research.

  1986cited by this paper
• Injury of nigral neurons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a tyrosine hydroxylase immunocytochemical study in monkey.

  1986cited by this paper
• ULTRASTRUCTURE OF NERVE CELL DEGENERATION IN THE SUBSTANTIA NIGRA IN EXPERIMENTAL MPTP-INDUCED PARKINSONISM IN THE MOUSE AND IN THE SQUIRREL MONKEY

  1986cited by this paper
• Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes.

  1985cited by this paper
• Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree--a new disease?

  1984cited by this paper
• Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism

  1984cited by this paper
• Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP.

  1984cited by this paper
• Classic and generalized variants of Pick's disease: A clinicopathological, ultrastructural, and immunocytochemical comparative study

  1984cited by this paper
• 1-Methyl-4-phenylpyridinium ion (MPP+): identification of a metabolite of MPTP, a toxin selective to the substantia nigra.

  1984cited by this paper
• Aspects of the ultrastructure of amyotrophic lateral sclerosis.

  1982cited by this paper
• An Electron Microscopic Study on Atypical Presenile Dementia with Numerous Lewy Bodies in the Cerebral Cortex

  1982cited by this paper
• CYTOLOGIC OBSERVATIONS ON AXOTOMIZED FELINE BETZ CELLS: 1. QUALITATIVE ELECTRON MICROSCOPIC FINDINGS

  1979cited by this paper
• Morphogenesis of the Hirano body in neurons of the squirrel monkey dorsal horn

  1978cited by this paper
• Lewy bodies in cerebral cortex. Report of three cases

  1978cited by this paper
• ULTRASTRUCTURE OF ASONAL REACTION IN RED NUCLEUS OF CAT

  1975cited by this paper
• ULTRASTRUCTURE OF RETROGRADE DEGENERATION IN THALAMUS OF RAT 1. NEURONAL SOMATA DENDRITES

  1973cited by this paper
• Pigments in the red nucleus and substantia nigra in man and in representative old and new world monkeys.

  1970cited by this paper
• Pigments in the red nucleus and substantia nigra in man and in representative old and new world monkeys.

  1970cited by this paper
• EXPERIMENTAL KURU ENCEPHALOPATHY IN CHIMPANZEES AND SPIDER MONKEYS: ELECTRON— MICROSCOPIC STUDIES

  1969cited by this paper
• Experimentak kuru encephalopathy in chimpanzees and spider monkeysElectron microscopic studies.

  1969cited by this paper
• Phase and Electron Microscopic Observations of Lewy Bodies and Melanin Granules in the Substantia Nigra and Locus Caeruleus in Parkinson's Disease

  1965cited by this paper
• THE PECULIAR CELLS OF PICK'S DISEASE: THEIR PATHOGENESIS AND DISTRIBUTION IN DISEASE

  1935cited by this paper

• Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting α-synuclein abnormalities in the substantia nigra.

  2016cites this paper
• Cell surface GRP78 and its interactions with CDNF and MANF

  2016cites this paper
• The Putative Causative Role of Environmental Toxins

  2016cites this paper
• The molecular mechanism of Chinese medicine Uncaria Rhynchophylla (gouteng) for inducing autophagy and protecting neurons in Parkinson's disease

  2015cites this paper
• The role of alpha-synuclein phosphorylation in synucleinopathies

  2014cites this paper
• Progress Towards Development Of Multifunctional, Dopamine D2/d3 Receptor Agonists As Symptomatic And Disease-Modifying Therapeutic Agents For Parkinson's Disease

  2013cites this paper
• RGS proteins in experimental Parkinsonism and L-DOPA-induced dyskinesia

  2012cites this paper
• Mitochondrial Dysfunction in Genetic Animal Models of Parkinson's Disease

  2012cites this paper
• Elucidating the role of post-translational modifications of alpha-synuclein using semisynthesis

  2012cites this paper
• The MPTP-Treated Primate, with Specific Reference to the Use of the Common Marmoset ( Callithrix jacchus )

  2011cites this paper
• Regional lysosomal malfunction underlies the selectivity of alpha-synuclein neurodegeneration

  2011cites this paper
• α-Synuclein Transgenic Mice Reveal Compensatory Increases in Parkinson's Disease-Associated Proteins DJ-1 and Parkin and Have Enhanced α-Synuclein and PINK1 Levels After Rotenone Treatment

  2010cites this paper
• EFECTO DE LA ADMINISTRACIÓN CRÓNICA DE LEVODOPA SOBRE LA ACTIVIDAD FUNCIONAL DE LA VÍA NIGROESTRIADA EN MACACOS CON PARKINSONISMO INDUCIDO POR MPTP

  2010cites this paper
• Animal models of neurological disease.

  2010cites this paper
• Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle

  2009cites this paper
• Cell Death Pathways in Parkinson's Disease: Role of Mitochondria

  2009cites this paper
• The Neuroprotective Role of Micronutrients in Parkinson’s Disease

  2009cites this paper
• Diseases of movement and system degenerations

  2008cites this paper
• Acute and Chronic Administration of 1-Methyl-4-Phenylpyridinium

  2008cites this paper
• Protein Kinase C-delta in dopaminergic system and experimental models of Parkinson's disease

  2008cites this paper
• MODIFICATIONS NEUROCHIMIQUES INDUITES PAR LA STIMULATION HAUTE FREQUENCE DU NOYAU SOUS-THALAMIQUE AU SEIN DES RESEAUX NEURONAUX IMPLIQUES DANS LES CIRCUITS MOTEURS ET LEURS INTERACTIONS AVEC UN TRAITEMENT A LA L-DOPA Etude par microdialyse intracérébrale chez le rat sain et hémiparkinsonien.

  2007cites this paper
• Behavioral correlates of unilateral dopamine depletion in the MPP+ rat model of Parkinson's Disease

  2007cites this paper
• The neuropathology of parkinsonism.

  2007cites this paper
• Mitochondria in the etiology of Parkinson's disease.

  2007cites this paper
• Experimental neuroprotective therapeutics in animal models of Huntington's disease and Parkinson's disease

  2006cites this paper
• An overview of Parkinson's disease and the cannabinoid system and possible benefits of cannabinoid-based treatments.

  2006cites this paper
• Rat model of Parkinson's disease: chronic central delivery of 1-methyl-4-phenylpyridinium (MPP+).

  2006cites this paper
• Modeling Neurodegenerative Diseases in vivo Review

  2006cites this paper
• Régulation de la fonction du récepteur dopaminergique D2 dans les neurones dopaminergiques

  2006cites this paper
• Insights into Parkinson's disease models and neurotoxicity using non-invasive imaging.

  2005cites this paper
• Reactive oxygen and nitrogen species: Weapons of neuronal destruction

  2005cites this paper
• Toxin-induced movement disorders.

  2005cites this paper
• MPTP-induced deficits in motor activity: Neuroprotective effects of the spintrapping agent, α-phenyl-tert-butyl-nitrone (PBN)

  2005cites this paper
• Molecular study of cell culture models of Parkinson's disease and Huntington's disease.

  2005cites this paper
• Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis.

  2005cites this paper
• Cell survival patterns in the pedunculopontine tegmental nucleus of methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys and 6OHDA-lesioned rats: evidence for differences to idiopathic Parkinson disease patients?

  2005cites this paper
• Molecular pathophysiology of Parkinson's disease.

  2005cites this paper
• Sporadic motor neuron disease with Lewy body-like hyaline inclusions

  2004cites this paper
• Enhanced substantia nigra mitochondrial pathology in human α-synuclein transgenic mice after treatment with MPTP111-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  2004cites this paper
• Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP.

  2004cites this paper
• Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson's disease.

  2003cites this paper
• Animal models of Parkinson's disease in rodents induced by toxins: an update.

  2003cites this paper
• Models of Parkinson's disease

  2003cites this paper
• Molecular Pathways of Neurodegeneration in Parkinson's Disease

  2003cites this paper
• Mitochondrial involvement in Parkinson's disease.

  2002cites this paper
• Cellular Reactions to Insult (Cellular Neuropathology)

  2002cites this paper
• Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease.

  2001cites this paper
• Experimental models of Parkinson's disease

  2001cites this paper
• Neurotoxicity of MPTP

  2001influential citation
• α‐Synuclein Up‐Regulation in Substantia Nigra Dopaminergic Neurons Following Administration of the Parkinsonian Toxin MPTP

  2000cites this paper
• Influence of MPP+ on the state of tubulin polymerisation in NGF‐differentiated PC12 cells

  1999cites this paper
• Multiple system atrophy: the putative causative role of environmental toxins.

  1999cites this paper
• Neuropathology of movement disorders.

  1998cites this paper
• Alterations of cytoskeletal tau protein of SH-SY5Y human neuroblastoma cells after exposure to MPTP.

  1998cites this paper
• Mitochondria in the etiology and pathogenesis of parkinson's disease

  1998cites this paper
• MPTP-Induced hemiparkinsonism in nonhuman primates 6-8 years after a single unilateral intracarotid dose.

  1998cites this paper
• Effects of Iron Overload on Lipid Peroxidation and Superoxide Dismutase Activities in the Brains of Aged Rats

  1998cites this paper
• Parkinson's disease.

  1997cites this paper
• MPTP: A Dopaminergic Neurotoxin

  1997cites this paper
• Pathogenesis of Parkinson's disease.

  1997cites this paper
• Highly Selective Neurotoxins

  1997influential citation
• Suspected MPTP-induced parkinsonism.

  1997cites this paper
• Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging.

  1997cites this paper
• Electron microscopy of Lewy bodies in the amygdala-parahippocampal region. Comparison with inclusion bodies in the MPTP-treated squirrel monkey.

  1996cites this paper
• The neuropathologic diagnosis of secondary parkinsonian syndromes.

  1996cites this paper
• Differential recovery of volitional motor function, lateralized cognitive function, dopamine agonist-induced rotation and dopaminergic parameters in monkeys made hemi-parkinsonian by intracarotid MPTP infusion.

  1995cites this paper
• Effect of Chronic Administration of 1,2,3,4-Tetrahydroisoquinoline and Its Derivatives on the Monkey: Immunohistochemical Study

  1995cites this paper
• Ultrastructure of eosinophilic inclusion bodies in the amygdala-parahippocampal region of aged squirrel monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a dopaminergic neurotoxin.

  1995cites this paper
• Intranuclear inclusion bodies in placental septal cells and their possible relation in placental cell degeneration

  1995cites this paper
• What is it that l‐deprenyl (selegiline) might do? *

  1994cites this paper
• Comparison of brain dopamine depletion induced by low-dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in young and aged rats.

  1994cites this paper
• Movement disorders.

  1993cites this paper
• Advances in Our Understanding of the Mechanisms of the Neurotoxicity of MPTP and Related Compounds

  1993cites this paper
• Subtypes in alzheimer's disease and the impact of excess disability: Recent findings

  1993cites this paper
• Plasticity of the nigrostriatal system in MPTP-treated mice. A biochemical and morphological correlation.

  1993cites this paper
• Does neuromelanin contribute to the vulnerability of catecholaminergic neurons in monkeys intoxicated with MPTP?

  1993cites this paper
• Age-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets.

  1993cites this paper
• New insights into the cause of Parkinson's disease

  1992cites this paper
• Neuronal changes in the nigrostriatal pathway of 1-methyl-4-phenylpyridine-treated mice.

  1992cites this paper
• The striatum and the globus pallidus : studies of internal and external organisation in the basal ganglia

  1992cites this paper
• MPTP-Induced Parkinsonism in Nonhuman Primates

  1991cites this paper
• Neuropeptide levels in the basal ganglia of aged common marmosets following prolonged treatment with MPTP

  1991cites this paper
• Parkinson’s Disease. From Clinical Aspects to Molecular Basis

  1991cites this paper
• MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease.

  1991cites this paper
• Topics of special interest in research of Parkinson’s disease

  1991cites this paper
• Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway.

  1991cites this paper
• The MPTP story: MAO activates tetrahydropyridine derivatives to toxins causing parkinsonism.

  1990cites this paper
• Do environmental toxins cause Parkinson's disease? A critical review

  1990cites this paper
• Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys.

  1990cites this paper
• MPTP-induced parkinsonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral field of symptomatic and asymptomatic vervet monkeys.

  1990cites this paper
• Selegiline and Parkinson’s Disease

  1990cites this paper
• Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for parkinsonism.

  1990cites this paper
• MPTP induced Parkinsonian syndrome: long term follow-up and neurophysiological study

  1990cites this paper
• Selegiline and Parkinson's disease. Protective and symptomatic considerations.

  1990cites this paper
• Drug-Induced Parkinsonism and Other Movement Disorders

  1990cites this paper
• MPTP‐induced parkinsonism as a model for Parkinson's disease

  1989cites this paper
• Early Diagnosis and Preventive Therapy in Parkinson’s Disease

  1989cites this paper
• Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse.

  1989cites this paper
• Cytoskeletal pathology of the Lewy bodies

  1989cites this paper
• Mechanisms underlying neuronal degeneration in Parkinson's disease: An experimental and theoretical treatise

  1989cites this paper